Lindbrook Capital, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$0
-100.0%
0
-100.0%
0.00%
Q2 2023$1,832
+18.4%
54
+25.6%
0.00%
Q1 2023$1,547
-56.1%
43
-45.6%
0.00%
Q4 2022$3,52179
+2533.3%
0.00%
Q3 2022$03
-66.7%
0.00%
Q2 2022$0
-100.0%
9
-82.7%
0.00%
Q1 2022$2,000
-96.2%
52
-94.7%
0.00%
-100.0%
Q3 2021$53,000
+152.4%
990
-1.0%
0.01%
+180.0%
Q1 2021$21,0000.0%1,000
-38.2%
0.01%
-16.7%
Q2 2020$21,0001,6180.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2021
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders